Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 14/20 | 0.80 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8284213 | 0.90 | SLC6A2 (1.00) | SLC6A2KCNH2SLC6A4CYP2D6SLC6A3 | |
| SCHEMBL14203005 | 0.90 | SLC6A2 (1.00) | SLC6A2KCNH2SLC6A4CYP2D6SLC6A3 | |
| SCHEMBL6438254 | 0.90 | SLC6A2 (1.00) | SLC6A2KCNH2SLC6A4CYP2D6SLC6A3 | |
| SCHEMBL14202975 | 0.90 | SLC6A2 (1.00) | SLC6A2KCNH2SLC6A4CYP2D6SLC6A3 | |
| Hydrochloric Acid SCHEMBL5038401 | 0.88 | SLC6A2 (0.98) | SLC6A2KCNH2SLC6A4CYP2D6SLC6A3 | |
| Hydrochloric Acid SCHEMBL5429601 | 0.88 | SLC6A2 (0.98) | SLC6A2KCNH2SLC6A4CYP2D6SLC6A3 | |
| Hydrochloric Acid SCHEMBL5038398 | 0.88 | SLC6A2 (0.98) | SLC6A2KCNH2SLC6A4CYP2D6SLC6A3 | |
| SCHEMBL5048152 | 0.88 | SLC6A2 (0.80) | SLC6A2SLC6A4CYP2D6SLC6A3 | |
| SCHEMBL5042331 | 0.88 | SLC6A2 (0.80) | SLC6A2CHRM3 | |
| SCHEMBL14203098 | 0.88 | SLC6A2 (0.77) | SLC6A2SLC6A4SLC6A3CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354920-B2 | Aryl and heteroaryl morpholine derivatives | ELI LILLY AND COMPANY (US) | 2008-04-08 | — | — | US | disclosed |
| US-20070105960-A1 | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY A CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | ELI LILY AND COMPANY (US) | 2007-01-18 | — | — | US | disclosed |
| US-20060241188-A1 | Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY (US) | 2006-10-26 | — | — | US | disclosed |
| EP-1660185-A2 | TREATMENT OF STUTTERING AND OTHER COMMUNICATION DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1660065-A2 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1660064-A2 | TREATMENT OF LEARNING DISABILITIES AND MOTOR SKILLS DISORDER WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20060003998-A1 | Aryl and heteroaryl morpholine derivatives | ELI LILLY AND COMPANY (IN) | 2006-01-05 | — | — | US | disclosed |
| WO-2005053663-A2 | NOREPINEPHRINE REUPTAKE INHIBITORS USEFUL FOR TREATMENT OF COGNITIVE FAILURE | ELI LILLY AND COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| EP-1534694-A1 | ARYL AND HETEROARYL MORPHOLINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005020976-A2 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005020975-A2 | TREATMENT OF LEARNING DISABILITIES AND MOTOR SKILLS DISORDER WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005021095-A2 | TREATMENT OF STUTTERING AND OTHER COMMUNICATION DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2004018441-A1 | ARYL AND HETEROARYL MORPHOLINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003998-A1 | Aryl and heteroaryl morpholine derivatives | ADRA2C, HTR2C, ADRB1 | SLC6A2 19/4885HTR1A 21/4885CHEK1 3550/4885 |
| US-20060241188-A1 | Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors | SLC6A2, SLC6A3, SLC6A4 | SLC6A2 1/4885HTR1A 15/4885CHEK1 4839/4885 |
| US-20070105960-A1 | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors | SLC6A2, SLC6A3, SLC6A4 | SLC6A2 1/4885HTR1A 28/4885CHEK1 4783/4885 |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | SLC6A2, SLC6A4, SLC6A3 | SLC6A2 1/4885HTR1A 17/4885CHEK1 4110/4885 |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | SLC6A2, SLC6A4, HTR5A | SLC6A2 1/4885HTR1A 6/4885CHEK1 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.